Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Duchenne Muscular Dystrophy
Duchenne Muscular Dystrophy
Sarepta preps $1.2B war chest as DMD gene therapy nears accelerated FDA nod
Fierce Biotech
Thu, 11/3/22 - 11:56 am
Sarepta Therapeutics
Duchenne Muscular Dystrophy
SRP-9001
gene therapy
Santhera seeks speedy FDA review of Duchenne drug vamorolone
Pharmaphorum
Fri, 10/28/22 - 10:26 am
Santhera
Duchenne Muscular Dystrophy
vamorolone
FDA
Sarepta asks FDA to approve first gene therapy for Duchenne muscular dystrophy
BioPharma Dive
Thu, 09/29/22 - 07:38 pm
Sarepta Therapeutics
Duchenne Muscular Dystrophy
FDA
gene therapy
SRP-9001
Pepgen aims to overtake Sarepta
EP Vantage
Wed, 09/28/22 - 11:00 am
Sarepta Therapeutics
PepGen
Duchenne Muscular Dystrophy
PGN-ED051
Eyeing accelerated approval for Duchenne gene therapy, Sarepta hopes to bring in $1B in bid for profitability
Endpoints
Tue, 09/13/22 - 10:35 am
Sarepta Therapeutics
Duchenne Muscular Dystrophy
gene therapy
FDA
After serious side effect, Sarepta and FDA realign on next-gen Duchenne drug with trial hold lifted
Endpoints
Tue, 09/6/22 - 10:48 am
Sarepta Therapeutics
Duchenne Muscular Dystrophy
vesleteplirsen
clinical trials
Did Sarepta Therapeutics Just Unveil a Breakthrough?
TheStreet.com
Wed, 08/17/22 - 11:37 pm
Sarepta Therapeutics
Duchenne Muscular Dystrophy
FDA
Sarepta to Expedite Timeline for Muscular Dystrophy Gene Therapy
BioSpace
Thu, 08/4/22 - 10:59 am
Sarepta Therapeutics
SRP-9001
Duchenne Muscular Dystrophy
Sarepta shares buoyed by pledge to seek an early swift review for Duchenne gene therapy
Fierce Biotech
Fri, 07/29/22 - 10:20 am
Sarepta Therapeutics
SRP-9001
Duchenne Muscular Dystrophy
Roche
accelerated approvals
Myocarditis case mars Sarepta DMD gene therapy readout
Pharmaforum
Thu, 07/7/22 - 10:23 am
Sarepta Therapeutics
gene therapy
Duchenne Muscular Dystrophy
SRP-9001
myocarditis
Another Duchenne clinical hold gets lifted, this time at Dyne Therapeutics
Endpoints
Tue, 07/5/22 - 10:45 am
Duchenne Muscular Dystrophy
clinical trials
Dyne Therapeutics
DYNE-251
As muscular dystrophy drug meets key goal, Italfarmaco plans march forward to regulators
MedCity News
Mon, 06/27/22 - 10:15 am
Duchenne Muscular Dystrophy
Italy
Ifalfarmco
givinostat
FDA suspends US testing of Sarepta Duchenne drug over safety concerns
BioPharma Dive
Thu, 06/23/22 - 08:04 pm
FDA
Sarepta Therapeutics
Duchenne Muscular Dystrophy
SRP-5051
PTC Ready to Take Another Shot at FDA Approval of DMD Drug
BioSpace
Tue, 06/21/22 - 10:58 am
PTC Therapeutics
Translarna
FDA
Duchenne Muscular Dystrophy
Pfizer, Sarepta team with fellow DMD gene therapy makers to get to the bottom of adverse events
Fierce Biotech
Tue, 05/17/22 - 10:31 pm
Duchenne Muscular Dystrophy
gene therapy
Pfizer
Sarepta Therapeutics
Genethon
Solid Biosciences
With Sarepta in its sights, PepGen prices IPO to fund DMD trials
Fierce Biotech
Fri, 05/6/22 - 10:55 am
PepGen
IPOs
Sarepta Therapeutics
Duchenne Muscular Dystrophy
FDA clears Pfizer to restart Duchenne gene therapy trial, with new safeguards
BioPharma Dive
Thu, 04/28/22 - 10:56 am
Pfizer
gene therapy
Duchenne Muscular Dystrophy
clinical trial
FDA
Roche delays DMD drug deadline, decides to rejig MS trials because of Ukraine war
Fierce Biotech
Tue, 04/26/22 - 10:33 am
Roche
Ocrevus
clinical trials
Duchenne Muscular Dystrophy
Astellas takes $170m charge as it drops DMD gene therapies
Pharmaforum
Fri, 04/22/22 - 10:48 am
Astellas
gene therapy
Duchenne Muscular Dystrophy
earnings
Pfizer aims to restart late-stage trial of Duchenne gene therapy following safety setback
BioPharma Dive
Thu, 02/10/22 - 08:04 pm
Pfizer
gene therapy
Duchenne Muscular Dystrophy
clinical trials
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
9
…
next ›
last »